Oesophageal cancer is one of the most aggressive malignancies of the gastrointestinal tract and represents a major global health burden. According to the World Health Organization and International Agency for Research on Cancer estimates, oesophageal cancer ranks among the top ten most common cancers worldwide and is a leading cause of cancer-related mortality due to its late presentation and aggressive biological behaviour. Despite improvements in diagnostic modalities and treatment strategies, the overall five-year survival rate remains poor, particularly in patients presenting with locally advanced disease. ¹ Locally advanced oesophageal cancer generally refers to tumors that have penetrated beyond the mucosal layer and involve the muscularis propria or adjacent structures, often accompanied by regional lymph node metastasis but without distant metastasis. In such cases, multimodality therapy has become the cornerstone of management. Surgery alone has historically been associated with high rates of local recurrence and poor survival outcomes, prompting the integration of systemic and locoregional therapies in the neoadjuvant setting. ² Two widely accepted neoadjuvant strategies for locally advanced esophageal cancer include neoadjuvant chemotherapy (NACT) and neoadjuvant chemoradiotherapy (NACRT) followed by surgical resection. Neoadjuvant chemotherapy aims to reduce tumor burden, eradicate micrometastatic disease, and improve resectability rates. Several clinical trials have demonstrated that systemic chemotherapy before surgery can enhance survival outcomes when compared with surgery alone. ³ On the other hand, neoadjuvant chemoradiotherapy combines systemic chemotherapy with radiotherapy to achieve both systemic disease control and improved local tumor eradication. Landmark studies such as the CROSS trial have demonstrated improved pathological response rates, R0 resection rates, and overall survival with chemoradiotherapy followed by surgery compared with surgery alone. ⁴ However, despite the established benefits of multimodality treatment, there remains ongoing debate regarding the optimal neoadjuvant strategy. While chemoradiotherapy tends to achieve higher pathological complete response rates and better local control, it may also be associated with increased treatment-related toxicity and perioperative complications. Conversely, chemotherapy alone may offer better systemic control with potentially lower treatment-related morbidity but may provide less effective local tumor regression. ⁵ The choice between these two strategies often depends on tumor histology, location, institutional protocols, and patient performance status. In regions with a high prevalence of squamous cell carcinoma, particularly in Asian populations, treatment strategies may differ from Western settings where adenocarcinoma predominates. ⁶ Several randomized controlled trials and meta-analyses have attempted to compare neoadjuvant chemotherapy with neoadjuvant chemoradiotherapy in terms of survival, pathological response, surgical outcomes, and treatment-related complications. Although some studies suggest superior local control and pathological response with chemoradiotherapy, others report comparable survival outcomes between the two modalities. ⁷ Given the persistent uncertainty regarding the relative effectiveness of these approaches, further comparative studies are necessary to clarify their impact on tumor downstaging, resectability, postoperative morbidity, and overall survival in patients with locally advanced esophageal cancer. Evaluating these outcomes is essential for optimizing treatment protocols and improving patient prognosis. ⁸ Therefore, comparative clinical studies assessing the outcomes of neoadjuvant chemotherapy and chemoradiotherapy in locally advanced esophageal cancer are of significant importance for guiding evidence-based treatment decisions and improving long-term survival. ⁹, ¹⁰ Aim To compare the clinical and oncological outcomes of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal cancer undergoing definitive surgical management. Objectives 1. To evaluate tumor downstaging rates following neoadjuvant chemotherapy and chemoradiotherapy. 2. To compare pathological complete response (pCR) rates between the two treatment modalities. 3. To assess differences in R0 resection rates after neoadjuvant therapy. 4. To compare treatment-related complications and postoperative morbidity between the two groups. 5. To evaluate overall survival and disease-free survival outcomes in patients receiving neoadjuvant chemotherapy versus chemoradiotherapy.

Study Design This study was designed as a prospective comparative observational study conducted to evaluate the outcomes of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal cancer. Place of Study The study was conducted at the Konaseema Institute of Medical Sciences and Research Foundation, located in Amalapuram, Andhra Pradesh, India. Patients were recruited from the Departments of Medical Oncology, Radiation Oncology, and General Surgery of the institution. Duration of Study The study was conducted over a 16-month period from November 2021 to February 2023. Study Population The study included patients diagnosed with locally advanced esophageal cancer who were planned for neoadjuvant therapy followed by surgical resection. Sample Size A total of 80 patients fulfilling the eligibility criteria were included in the study. Patients were divided into two groups: • Group A (n = 40): Patients receiving neoadjuvant chemotherapy (NACT) followed by surgery. • Group B (n = 40): Patients receiving neoadjuvant chemoradiotherapy (NACRT) followed by surgery. Inclusion Criteria 1. Patients aged 18–75 years. 2. Histologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus. 3. Patients diagnosed with locally advanced esophageal cancer (Stage II–III) based on clinical and radiological evaluation. 4. Patients considered fit for neoadjuvant therapy and surgical resection. 5. Patients who provided written informed consent to participate in the study. Exclusion Criteria 1. Patients with distant metastasis (Stage IV disease). 2. Patients who had received prior chemotherapy or radiotherapy for esophageal cancer. 3. Patients with severe comorbid illnesses precluding surgery or neoadjuvant therapy. 4. Patients with recurrent esophageal cancer. 5. Pregnant or lactating women. Diagnostic Evaluation All patients underwent a detailed clinical assessment and staging work-up, which included: • Upper gastrointestinal endoscopy with biopsy for histopathological confirmation. • Contrast-enhanced computed tomography (CECT) of the chest and abdomen. • Endoscopic ultrasound (EUS) where available for local staging. • Routine hematological and biochemical investigations. Tumors were staged according to the TNM classification of the American Joint Committee on Cancer staging system (8th edition). Treatment Protocol Group A: Neoadjuvant Chemotherapy (NACT) Patients received platinum-based combination chemotherapy, commonly consisting of: • Cisplatin (75 mg/m² on day 1) • 5-Fluorouracil (1000 mg/m²/day continuous infusion for 4 days) Chemotherapy was administered every 3 weeks for 2–3 cycles depending on patient tolerance and response. Group B: Neoadjuvant Chemoradiotherapy (NACRT) Patients received concurrent chemotherapy with external beam radiotherapy: • Radiotherapy: Total dose of 41.4–50.4 Gy delivered in 23–28 fractions over 5–6 weeks. • Concurrent Chemotherapy: Weekly carboplatin and paclitaxel regimen. Surgical Management Following completion of neoadjuvant therapy and restaging evaluation, patients underwent definitive surgical resection, typically transthoracic or transhiatal esophagectomy with regional lymphadenectomy depending on tumor location and surgical feasibility. Outcome Measures The following parameters were evaluated: 1. Tumor downstaging after neoadjuvant therapy. 2. Pathological complete response (pCR). 3. R0 resection rate (complete tumor resection with negative margins). 4. Postoperative complications and morbidity. 5. Short-term survival outcomes and disease recurrence. Data Collection Clinical data including demographic details, tumor characteristics, treatment details, operative findings, histopathological results, and postoperative outcomes were recorded using a structured data collection proforma. Statistical Analysis Data were entered and analyzed using SPSS software version 25.0. Continuous variables were expressed as mean ± standard deviation, while categorical variables were presented as frequency and percentage. • Chi-square test was used to compare categorical variables between the two groups. • Independent t-test was used for comparison of continuous variables. • A p-value < 0.05 was considered statistically significant. Ethical Considerations The study protocol was reviewed and approved by the Institutional Ethics Committee of the Konaseema Institute of Medical Sciences and Research Foundation. Written informed consent was obtained from all participants prior to enrollment in the study.

A total of 80 patients with locally advanced esophageal cancer were included in the study conducted at the Konaseema Institute of Medical Sciences and Research Foundation, Amalapuram. The patients were divided into two groups: Group A (Neoadjuvant Chemotherapy – NACT, n = 40) and Group B (Neoadjuvant Chemoradiotherapy – NACRT, n = 40). Baseline demographic and clinical characteristics were comparable between the two groups. Table:- 1. Demographic Characteristics of the Study Population Variable NACT (n=40) NACRT (n=40) p-value Mean age (years) 56.2 ± 9.4 57.1 ± 8.8 0.64 Male 28 (70%) 29 (72.5%) 0.81 Female 12 (30%) 11 (27.5%) Squamous cell carcinoma 30 (75%) 31 (77.5%) 0.79 Adenocarcinoma 10 (25%) 9 (22.5%) The majority of patients in both groups were males, and squamous cell carcinoma was the predominant histological subtype. Table:2. Tumor Stage Distribution Before Treatment Clinical Stage NACT (n=40) NACRT (n=40) Stage II 16 (40%) 15 (37.5%) Stage III 24 (60%) 25 (62.5%) Tumor downstaging was significantly higher in the NACRT group compared to the NACT group. Table 4. Pathological Complete Response (pCR) Outcome NACT (n=40) NACRT (n=40) p-value pCR 4 (10%) 10 (25%) 0.048 Residual tumor 36 (90%) 30 (75%) The pathological complete response rate was higher in patients receiving chemoradiotherapy. Table 5: R0 Resection Rate Resection Status NACT (n=40) NACRT (n=40) p-value R0 resection 30 (75%) 35 (87.5%) 0.14 R1/R2 resection 10 (25%) 5 (12.5%) Although the R0 resection rate was higher in the NACRT group, the difference was not statistically significant. Table: 6. Postoperative Complications Complication NACT (n=40) NACRT (n=40) Pulmonary complications 6 (15%) 9 (22.5%) Anastomotic leak 3 (7.5%) 4 (10%) Wound infection 5 (12.5%) 6 (15%) No complications 26 (65%) 21 (52.5%) Postoperative complications were slightly higher in the chemoradiotherapy group, particularly pulmonary complications. Table:7. Short-Term Survival and Recurrence (Follow-up up to 12 months) Outcome NACT (n=40) NACRT (n=40) p-value Alive without recurrence 26 (65%) 31 (77.5%) 0.21 Recurrence 8 (20%) 5 (12.5%) Mortality 6 (15%) 4 (10%) Patients treated with neoadjuvant chemoradiotherapy showed better disease control, though the difference in short-term survival did not reach statistical significance.

The management of locally advanced esophageal cancer has evolved significantly over the past few decades, with multimodality therapy becoming the standard approach to improve survival and resectability. In the present study conducted at the Konaseema Institute of Medical Sciences and Research Foundation, Amalapuram, outcomes of neoadjuvant chemotherapy (NACT) were compared with neoadjuvant chemoradiotherapy (NACRT) in 80 patients with locally advanced esophageal cancer. The findings demonstrated that chemoradiotherapy resulted in higher tumor downstaging and pathological complete response rates compared with chemotherapy alone. In this study, the mean age of patients was around 56–57 years, with a predominance of male patients and squamous cell carcinoma as the most common histological subtype. These findings are consistent with previous epidemiological studies, which reported that esophageal cancer occurs more commonly in males and that squamous cell carcinoma remains the dominant histological type in many Asian populations. ¹¹ The present study demonstrated higher tumor downstaging in the NACRT group (72.5%) compared with the NACT group (50%), indicating improved local tumor control with combined modality therapy. Similar observations were reported in several clinical trials, which demonstrated that the addition of radiotherapy to chemotherapy enhances tumor regression and improves surgical outcomes. ¹² The pathological complete response (pCR) rate observed in our study was 25% in the NACRT group compared with 10% in the NACT group. Pathological complete response is an important prognostic indicator and has been associated with improved long-term survival in patients with esophageal cancer. Previous randomized trials have reported pCR rates ranging from 20–30% with neoadjuvant chemoradiotherapy, which is comparable to the findings of the present study. ¹³ Another important finding of the present study was the higher R0 resection rate in the NACRT group (87.5%) compared with the NACT group (75%), although the difference was not statistically significant. Achieving R0 resection is a key determinant of long-term survival, and neoadjuvant therapy plays an important role in improving the likelihood of complete tumor resection. Similar results have been reported in multicenter trials comparing different neoadjuvant strategies. ¹⁴ However, our study also demonstrated a slightly higher incidence of postoperative complications in the NACRT group, particularly pulmonary complications. This may be attributed to the effects of thoracic radiotherapy and combined treatment-related toxicity. Previous studies have also noted increased perioperative morbidity in patients receiving chemoradiotherapy, although the overall survival benefits often outweigh these risks. ¹⁵ In terms of short-term survival and recurrence, the NACRT group showed a trend toward improved outcomes compared with the NACT group. A greater proportion of patients in the chemoradiotherapy group remained disease-free during the follow-up period, while recurrence and mortality rates were lower compared with the chemotherapy group. These findings support the growing evidence that combined modality therapy improves both local disease control and long-term survival in patients with locally advanced esophageal cancer. ¹⁶ The results of the present study are also supported by several meta-analyses which have shown that neoadjuvant chemoradiotherapy significantly improves overall survival, disease-free survival, and pathological response rates compared with chemotherapy alone or surgery alone. ¹⁷ Despite these findings, certain limitations of the present study should be acknowledged. The relatively small sample size and single-center design may limit the generalizability of the results. Additionally, the duration of follow-up was relatively short, preventing detailed evaluation of long-term survival outcomes. Larger multicenter studies with longer follow-up periods are required to further clarify the optimal neoadjuvant strategy for locally advanced esophageal cancer. ¹⁸ Overall, the findings of this study highlight the benefits of neoadjuvant chemoradiotherapy in improving tumor response and surgical outcomes, while also emphasizing the need to balance these benefits against the potential increase in treatment-related complications.¹⁹,²⁰

The present study demonstrates that neoadjuvant chemoradiotherapy provides better tumor downstaging and higher pathological complete response rates compared with neoadjuvant chemotherapy alone in patients with locally advanced esophageal cancer. Although postoperative complications were slightly higher in the chemoradiotherapy group, the improved tumor response and higher R0 resection rates suggest a potential advantage of this treatment modality. Therefore, neoadjuvant chemoradiotherapy followed by surgical resection appears to be a more effective multimodality treatment strategy for locally advanced esophageal cancer, particularly in terms of local tumor control and pathological response. However, larger prospective studies with longer follow-up are required to confirm these findings and to evaluate long-term survival benefits.

1.Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020. CA Cancer J Clin. 2021;71(3):209-249. 2.Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383-2396. 3.Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy. Lancet. 2002;359:1727-1733. 4.van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal cancer. N Engl J Med. 2012;366:2074-2084. 5.Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery vs surgery alone. Lancet Oncol. 2015;16:1090-1098. 6.Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal cancer. Gastroenterology. 2018;154:360-373. 7. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy. Lancet Oncol. 2011;12:681-692. 8)Klevebro F, Alexandersson von Döbeln G, Wang N, et al. A randomized trial of neoadjuvant chemotherapy vs chemoradiotherapy. Ann Oncol. 2016;27:660-667. 9.Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery. Lancet Oncol. 2014;15:1224-1235. 10.Pasquali S, Yim G, Vohra RS, et al. Survival after neoadjuvant treatment for esophageal cancer. Ann Surg. 2017;265:481-491. 11.Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371:2499-2509. 12.Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma. Lancet Oncol. 2011;12:681-692. 13.Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for esophageal cancer. Lancet Oncol. 2015;16:1090-1098. 14.Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380:152-162. 15.Markar SR, Noordman BJ, Mackenzie H, et al. Multimodality treatment for esophageal adenocarcinoma. Ann Surg. 2017;266:284-289. 16.Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastro-esophageal cancer. N Engl J Med. 2006;355:11-20. 17.Pasquali S, Yim G, Vohra RS, et al. Survival after neoadjuvant treatment for esophageal cancer. Ann Surg. 2017;265:481-491. 18.Klevebro F, Alexandersson von Döbeln G, Wang N, et al. Randomized clinical trial of neoadjuvant chemotherapy versus chemoradiotherapy. Ann Oncol. 2016;27:660-667. 19.Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy versus chemoradiotherapy. J Clin Oncol. 2009;27:851-856. 20.van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal cancer. N Engl J Med. 2012;366:2074-2084.